Celltrion has revealed the nonclinical results of its obesity treatment candidate that simultaneously stimulates four hormonal pathways, marking it as the world's first 'quadruple action' drug.
The company announced on November 4 that it presented the nonclinical research findings for its quadruple action obesity treatment candidate, 'CT-G32/SCO-940,' at the global conference 'TIDES Europe' held in Amsterdam from November 3 to 5. This research was conducted in collaboration with Japan's Sucro Pharma.
CT-G32/SCO-940 targets four hormonal pathways—GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), glucagon, and amylin—within a single candidate. Based on the disclosed development status, this combination of quadruple action for an obesity treatment is a world first.
The presentation included pharmacological results related to receptor-specific cell activity assessments and weight, body composition, and insulin levels in diet-induced obese rats. In evaluations using obese animal models, CT-G32/SCO-940 demonstrated greater weight loss effects compared to the representative triple-action drug, retatrutide, when administered at the same dosage. The company explained that during the weight loss process, the proportion of lean mass reduction, including muscle and bone, was relatively lower than that of the comparison drug. This suggests the potential for effective body composition management alongside weight loss, minimizing muscle loss.
The drug also showed effectiveness in reducing excessive blood insulin levels, a common issue among obese patients, indicating its potential to extend beyond obesity treatment to metabolic disease therapy. In primate pharmacokinetic evaluations, the drug exhibited prolonged exposure within the body. Based on this, Celltrion stated that it could develop a once-weekly dosing formulation to enhance patient convenience.
Celltrion plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in February 2024. If regulatory reviews proceed smoothly, the company aims to initiate global clinical trials with the first patient dosing in the second quarter of the same year. The company intends to develop CT-G32/SCO-940 as a 'first-in-class' new drug that addresses unmet needs, such as individual efficacy differences seen in existing GLP-1-based treatments and muscle loss during weight loss.
A Celltrion representative stated, "We have confirmed the differentiation potential of our core pipeline in nonclinical studies with the world's first quadruple action combination, surpassing existing dual and triple-action drugs. We aim to develop it as a next-generation treatment that encompasses not only weight loss but also improvements in body composition and metabolism."
The company announced on November 4 that it presented the nonclinical research findings for its quadruple action obesity treatment candidate, 'CT-G32/SCO-940,' at the global conference 'TIDES Europe' held in Amsterdam from November 3 to 5. This research was conducted in collaboration with Japan's Sucro Pharma.
CT-G32/SCO-940 targets four hormonal pathways—GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), glucagon, and amylin—within a single candidate. Based on the disclosed development status, this combination of quadruple action for an obesity treatment is a world first.
The presentation included pharmacological results related to receptor-specific cell activity assessments and weight, body composition, and insulin levels in diet-induced obese rats. In evaluations using obese animal models, CT-G32/SCO-940 demonstrated greater weight loss effects compared to the representative triple-action drug, retatrutide, when administered at the same dosage. The company explained that during the weight loss process, the proportion of lean mass reduction, including muscle and bone, was relatively lower than that of the comparison drug. This suggests the potential for effective body composition management alongside weight loss, minimizing muscle loss.
The drug also showed effectiveness in reducing excessive blood insulin levels, a common issue among obese patients, indicating its potential to extend beyond obesity treatment to metabolic disease therapy. In primate pharmacokinetic evaluations, the drug exhibited prolonged exposure within the body. Based on this, Celltrion stated that it could develop a once-weekly dosing formulation to enhance patient convenience.
Celltrion plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in February 2024. If regulatory reviews proceed smoothly, the company aims to initiate global clinical trials with the first patient dosing in the second quarter of the same year. The company intends to develop CT-G32/SCO-940 as a 'first-in-class' new drug that addresses unmet needs, such as individual efficacy differences seen in existing GLP-1-based treatments and muscle loss during weight loss.
A Celltrion representative stated, "We have confirmed the differentiation potential of our core pipeline in nonclinical studies with the world's first quadruple action combination, surpassing existing dual and triple-action drugs. We aim to develop it as a next-generation treatment that encompasses not only weight loss but also improvements in body composition and metabolism."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.